Tenaya Therapeutics Inc TNYA

$0.39 +0.00 (0.26%)

Valuation

Market cap
87,001,000
Revenue TTM
$0
Net income TTM
$-90,600,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,698,800
Avg volume
2,938,054
Day's range
$0.38 – $0.40
Shares out
224,230,000
Stochastic %K
14%
Beta
2.87
Analysts
Strong Sell
Price target
$9.33

Price

Company profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, wh...

Show more

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 825 6990
Website
https://www.tenayatherapeutics.com
Address
171 Oyster Point Boulevard, Suite 500, South San Francisco, United States

Latest news

Stocktwits

BIOVIC Oct 23, 9:01 PM
$TNYA filed its definitive proxy today. Same proposed 1-for-10 to 1-for-25 reverse-split range; shareholder vote Dec. 9. Not an approved or executed split. The board retains discretion not to proceed. Authorized shares remain unchanged, so future dilution risk still matters. This filing advances the known process; it does not announce a new offering. (SEC filing) Still holding. Not selling because of bad tape alone, but not ignoring financing risk either. NFA.
0 replies
TwongStocks Oct 23, 8:53 PM
$TNYA Definitive proxy has been filed. Confirms that a special shareholder meeting will be held Dec 9. They are asking for authorization to do a reverse split, in the range of 1:10 to 1:25. https://www.sec.gov/Archives/edgar/data/1858848/000119312526430591/tnya-20261023.htm Record date is Monday Oct 19. You had to be a shareholder at the close on Oct 19 to be eligible to vote. There were 227,928,240 shares outstanding as of Oct 19.
0 replies
BIOVIC Oct 23, 8:07 PM
$TNYA Friday close: $0.3890, +0.26% while XBI fell 1.37%. Volume 1.68M vs 2.73M average. Finished near the midpoint of the $0.3813–$0.3961 range. Held up against a red sector, but light volume keeps me from calling a reversal. I want stronger buying and follow-through. Still holding. Not selling because of bad tape alone, but not ignoring it either. Following the evidence, not forcing a bullish story.
0 replies
dig_THAT_girl Oct 23, 5:01 PM
$TNYA Irish
2 replies
Kostcoboi Oct 23, 3:05 PM
$TNYA
0 replies
BIOVIC Oct 23, 1:02 PM
$TNYA
0 replies
Damage111 Oct 23, 11:00 AM
$TNYA
0 replies
busyworx Oct 22, 6:17 PM
$TNYA So we're just going to sit at this 50% mark for awhile🤔.....Long term range... hopefully not too long.😵‍💫
0 replies